Jan 3, 2023 | News
Marvel Biosciences Corp. (TSV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has successfully completed its dose-ranging toxicology studies in rats and dogs, for its lead drug...
Dec 23, 2022 | News
Marvel Biosciences Inc. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has entered into a Letter Agreement for Market Stabilization and Liquidity Services (the...
Dec 12, 2022 | News
Calgary, Alberta – (December 12, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), announces it has initiated its 10-day, dose-ranging toxicology study, using dogs, for...
Dec 7, 2022 | News
Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has initiated its 7-day dose-ranging, toxicology study, using rats, for its lead molecule MB-204....
Nov 24, 2022 | News
CALGARY, Alberta – (November 24, 2022) – Marvel Biosciences Inc. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that, effective November 23, 2022, Mr. Babak Pedram has joined...
Nov 22, 2022 | News
Calgary, Alberta–(November 22, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that in a recent study done by the Company, its lead drug candidate...
